Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 15, 2016

Evaluation of the effects of roselle (Hibiscus sabdariffa L.) on oxidative stress and serum levels of lipids, insulin and hs-CRP in adult patients with metabolic syndrome: a double-blind placebo-controlled clinical trial

  • Sedigheh Asgary , Rasool Soltani EMAIL logo , Mohsen Zolghadr , Mahtab Keshvari and Nizal Sarrafzadegan


Background: Roselle (Hibiscus sabdariffa L.) is a plant with antihyperlipidemic and antihypertensive effects. This study aimed to evaluate the effects of roselle calyces on the serum levels of lipids and insulin, inflammation, and oxidative stress in patients with metabolic syndrome (MetS).

Methods: Forty adult patients with MetS were randomly assigned to receive either 500 mg of H. sabdariffa calyx powder or placebo once daily for 4 weeks. Systolic and diastolic blood pressures (SBP and DBP) and BMI (body mass index) as well as fasting serum levels of glucose (FPG; fasting plasma glucose), insulin, lipoproteins, triglycerides (TG), high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde (MDA) were determined pre- and post-intervention and compared.

Results: H. sabdariffa significantly reduced serum TG (p=0.044) and SBP (p=0.049) compared to placebo. All other variables were not significantly affected by the interventions.

Conclusions: Daily consumption of 500 mg of H. sabdariffa L. calyx powder can decrease SBP and serum TG in MetS patients.

Author contributions

All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356–9.10.1001/jama.287.3.356Search in Google Scholar

2. Ohkuma T, Fujii H, Iwase M, Ogata-Kaizu S, Ide H, Kikuchi Y, et al. U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: The Fukuoka Diabetes Registry. Metab Clin Exp 2014;63:484–91.10.1016/j.metabol.2013.12.001Search in Google Scholar

3. Kendall DM, Harmel AP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 2002;8:S635–53.Search in Google Scholar

4. Lorenzo C, Okoloise M, Williams K, Stern M, Haffner S. The metabolic syndrome as predictor of type 2 diabetes. The San Antonio Heart Study. Diab Care 2003;26:3153–9.10.2337/diacare.26.11.3153Search in Google Scholar

5. Martins D, Tareen N, Ogedegbe G, Pan D, Norris K. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from the NHANES-II mortality follow-up. J Natl Med Assoc 2008;100:565–71.10.1016/S0027-9684(15)31304-3Search in Google Scholar

6. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384–9.10.2337/diabetes.50.10.2384Search in Google Scholar PubMed

7. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and update meta-analyses. BMJ 2000;321:199–204.10.1136/bmj.321.7255.199Search in Google Scholar PubMed PubMed Central

8. Belfki H, Ben Ali S, Bougatef S, Ben Ahmed D, Haddad N, Jmal A, et al. Relationship of C-reactive protein with components of the metabolic syndrome in a Tunisian population. Eur J Intern Med 2012;23:e5–9.10.1016/j.ejim.2011.10.011Search in Google Scholar PubMed

9. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diab Res Clin Pract 2006;71:92–100.10.1016/j.diabres.2005.05.003Search in Google Scholar PubMed

10. Nakamura H, Ito H, Egami Y, Kaji Y, Maruyama T, Koike G, et al. Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diab Res Clin Pract 2008;79:330–6.10.1016/j.diabres.2007.09.004Search in Google Scholar PubMed

11. Mahadik SR, Deo SS, Mehtalia DS. Relation of C-reactive protein with the components of metabolic syndrome in Asian subjects. Diab Metab Syndr 2008;2:29–35.10.1016/j.dsx.2007.09.009Search in Google Scholar

12. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: The oxidative stress. Nutr Metab Cardiovasc Dis 2010;20:72–7.10.1016/j.numecd.2009.06.002Search in Google Scholar

13. Caimi G, Hopps E, Montana M, Noto D, Canino B, Lo Presti R, et al. Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diab Metab Syndr 2012;6:132–5.10.1016/j.dsx.2012.09.012Search in Google Scholar

14. Demircan N, Gurel A, Armuctu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malonildialdehyde and total antioxidant status in patients with metabolic syndrome. Med Sci Monit 2008;14:97–101.Search in Google Scholar

15. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations. Diabetes 2003;52:2346–52.10.2337/diabetes.52.9.2346Search in Google Scholar

16. Aziz Z, Wong SY, Chong NJ. Effects of Hibiscus sabdariffa L. on serum lipids: a systematic review and meta-analysis. J Ethnopharmacol 2013;150:442–50.10.1016/j.jep.2013.09.042Search in Google Scholar

17. Ali BH, Wabel NA, Blunden G. Phytochemical, pharmacological and toxicological aspects of Hibiscus sabdariffa L.: a review. Phytother Res 2005;19:369–75.10.1002/ptr.1628Search in Google Scholar

18. Jonadet M, Bastide J, Bastide P, Boyer B, Carnat A, Lamaison J. In vitro enzyme inhibitory and in vivo cardioprotective activities of Hibiscus sabdariffa L. J Pharm Belg 1990;45:120–4.Search in Google Scholar

19. Chen C-C, Chou F-P, Ho Y-C, Lin W-L, Wang C-P, Kao E-S, et al. Inhibitory effects of Hibiscus sabdariffa L extract on low-density lipoprotein oxidation and anti-hyperlipidemia in fructose-fed and cholesterol-fed rats. J Sci Food Agric 2004;84:1989–96.10.1002/jsfa.1872Search in Google Scholar

20. Abu-Irmaileh BE, Afifi FU. Herbal medicine in Jordan with special emphasis on commonly used herbs. J Ethnopharmacol 2003;89:193–7.10.1016/S0378-8741(03)00283-6Search in Google Scholar

21. Dafallah AA, Al-Mustafa Z. Investigation of the anti-inflammatory activity of Acacia nilotica and Hibiscus sabdariffa. Am J Chin Med 1996;24:263–9.10.1142/S0192415X96000323Search in Google Scholar PubMed

22. Hasanloo T, Sepehrifar R, Hajimehdipoor H. Levels of phenolic compounds and their effects on antioxidant capacity of wild Vaccinium arctostaphylos L. (Qare-Qat) collected from different regions of Iran. Turk J Biol 2011;35:371–7.10.3906/biy-0909-96Search in Google Scholar

23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97.10.1001/jama.285.19.2486Search in Google Scholar PubMed

24. Gurrola-Díaz CM, García-López PM, Sánchez-Enríquez S, Troyo-Sanromán R, Andrade-González I, Gómez-Leyva JF. Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy). Phytomedicine 2010;17:500–5.10.1016/j.phymed.2009.10.014Search in Google Scholar PubMed

25. Ochani PC, D’Mello P. Antioxidant and antihyperlipidemic activity of Hibiscus sabdariffa Linn. leaves and calyces extracts in rats. J Exp Biol 2009;47:276–82.Search in Google Scholar

26. Hirunpanich V, Utaipat A, Morales NP, Bunyapraphatsara N, Sato H, Herunsale A, et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. J Ethnopharmacol 2006;103:252–60.10.1016/j.jep.2005.08.033Search in Google Scholar PubMed

27. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M, Fatehi F. Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. J Altern Complement Med 2009;15:899–903.10.1089/acm.2008.0540Search in Google Scholar PubMed

28. Kuriyan R, Kumar D, R R, Kurpad AV. An evaluation of the hypolipidemic effect of an extract of Hibiscus sabdariffa leaves in hyperlipidemic Indians: a double blind, placebo controlled trial. BMC Complement Altern Med 2010;10:27.10.1186/1472-6882-10-27Search in Google Scholar PubMed PubMed Central

29. Olatunji LA, Adebayo JO, Oguntoye OB, Olatunde NO, Olatunji VA, Soladoye AO. Effects of aqueous extracts of petals of red and green Hibiscus sabdariffa on plasma lipid and hematological variables in rats. Pharm Biol 2005;43:471–4.10.1080/13880200590963934Search in Google Scholar

30. Farombi EO, Ige OO. Hypolipidemic and antioxidant effects of ethanolic extract from dried calyx of Hibiscus sabdariffa in alloxan-induced diabetic rats. Fundam Clin Pharmacol 2007;21:601–9.10.1111/j.1472-8206.2007.00525.xSearch in Google Scholar PubMed

31. Mohagheghi A, Maghsoud S, Khashayar P, Ghazi-Khansari M. The effect of Hibiscus sabdariffa on lipid profile, creatinine, and serum electrolytes: a randomized clinical trial. ISRN Gastroenterol 2011;2011:4.10.5402/2011/976019Search in Google Scholar PubMed PubMed Central

32. Chang HC, Peng CH, Yeh DM, Kao ES, Wang CJ. Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Food Funct 2014;5:734–9.10.1039/c3fo60495kSearch in Google Scholar PubMed

33. Mojiminiyi FB, Dikko M, Muhammad BY, Ojobor PD, Ajagbonna OP, Okolo RU, et al. Antihypertensive effect of an aqueous extract of the calyx of Hibiscus sabdariffa. Fitoterapia 2007;78:292–7.10.1016/j.fitote.2007.02.011Search in Google Scholar PubMed

34. McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr 2010;140:298–303.10.3945/jn.109.115097Search in Google Scholar PubMed

35. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M, Fatehi F, Noori-Shadkam M. The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. J Hum Hypertens 2009;23:48–54.10.1038/jhh.2008.100Search in Google Scholar PubMed

36. Herrera-Arellano A, Flores-Romero S, Chávez-Soto MA, Tortoriello J. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine 2004;11:375–82.10.1016/j.phymed.2004.04.001Search in Google Scholar PubMed

37. Joven J, March I, Espinel E, Fernández-Arroyo S, Rodríguez-Gallego E, Aragonès G, et al. Hibiscus sabdariffa extract lowers blood pressure and improves endothelial function. Mol Nutr Food Res 2014;58:1374–8.10.1002/mnfr.201300774Search in Google Scholar PubMed

Received: 2015-5-12
Accepted: 2016-1-20
Published Online: 2016-3-15
Published in Print: 2016-6-1

©2016 by De Gruyter

Downloaded on 25.3.2023 from
Scroll Up Arrow